Launch Of Vyvgart Exceeds Argenx’s Expectations

‘Pipeline in A Product’ Off To Strong Start In US

Tim Van Hauwermeiren, CEO of Argenx, has been on the road with the firm's field force for the US launch of Vyvgart for generalized myasthenia gravis and has been enthused by the positive response from physicians.

false start
Argenx fast out of the blocks with Vyvgart launch • Source: Alamy

The decision to go it alone in marketing the rare disease drug Vyvgart in the US looks a wise one for argenx N.V., with the Belgian-Dutch biotech off to a strong start following the therapy's approval for generalized myasthenia gravis (gMG).

The US Food and Drug Administration gave the green light to Vyvgart (efgartigimod), Argenx’s first approved product, on 17 December...

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

More from New Products

More from Scrip